Bioventus (NYSE:BVS - Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens on Tuesday, May 7th. Analysts expect Bioventus to post earnings of ($0.05) per share for the quarter. Bioventus has set its FY 2024 guidance at 0.120-0.200 EPS.Persons that are interested in participating in the company's earnings conference call can do so using this link.
Bioventus (NYSE:BVS - Get Free Report) last posted its earnings results on Tuesday, March 12th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.01. The company had revenue of $135.42 million for the quarter, compared to analyst estimates of $124.84 million. Bioventus had a negative net margin of 30.49% and a positive return on equity of 2.25%. On average, analysts expect Bioventus to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Bioventus Trading Down 2.7 %
Shares of NYSE BVS traded down $0.11 during midday trading on Tuesday, reaching $3.96. 113,131 shares of the stock were exchanged, compared to its average volume of 144,547. The stock has a market capitalization of $313.51 million, a P/E ratio of -1.58 and a beta of 0.50. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.01 and a current ratio of 1.53. The company has a 50 day simple moving average of $4.93 and a 200 day simple moving average of $4.55. Bioventus has a twelve month low of $0.86 and a twelve month high of $6.08.
Insider Activity at Bioventus
In other news, CFO Mark Leonard Singleton sold 5,541 shares of the company's stock in a transaction that occurred on Friday, March 22nd. The shares were sold at an average price of $5.39, for a total value of $29,865.99. Following the transaction, the chief financial officer now directly owns 25,665 shares in the company, valued at approximately $138,334.35. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders have sold 15,720 shares of company stock worth $80,435. Company insiders own 29.10% of the company's stock.
Wall Street Analyst Weigh In
Separately, Craig Hallum raised their target price on Bioventus from $6.00 to $9.00 and gave the stock a "buy" rating in a research note on Wednesday, March 13th.
Read Our Latest Report on Bioventus
About Bioventus
(
Get Free Report)
Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.
Recommended Stories
Before you consider Bioventus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventus wasn't on the list.
While Bioventus currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
